Skip to main content
. 2018 May 7;7(7):e1404216. doi: 10.1080/2162402X.2017.1404216

Figure 6.

Figure 6.

scL-53 treatment alone in vivo modestly alters MOC1 tumor growth but enhances tumor cell immunogenicity and effector immune cell tumor infiltration. A, established MOC1 tumors (WT B6 mice) were treated with scL-53 and digested whole tumors were assayed for the expression of human TP53 (clone DO-1) via western blot. B, treatment of established MOC1 tumors with single agent scL-53 (30 μg/injection, twice weekly x 3 weeks) resulted in a modest primary tumor growth delay (upper panel) and modest but statistically significant enhancement of survival (lower panel). Expression of MOC1 tumor cell (CD45.2−CD31−) surface components of immunogenicity (C, MFI shown) and tumor immune infiltration (D, absolute number of cells per 1 × 104 live cells collected) were assessed following treatment of established MOC1 tumors via flow cytometry. Identified CD45.2+ cells included CD8 TIL (CD3+CD8+), CD4 TIL (CD3+CD4+), dendritic cells (CD11c+CD11b+/−PDCA+/−), macrophages (CD11b+F4/80+), gMDSC (CD11b+Ly6G+Ly6Cint) and mMDSC (CD11b+Ly6G−Ly6Chi). Shown are representative results from one of two independent in vivo experiments. Control mice for these experiments received TVI of PBS alone. *, p < 0.05; **, p < 0.01.